The Phase 1 data strongly support Q12W dosing and a best-in-class anti-APRIL profile, de-risking the NAVIGATE-2 Phase 2 trial. Watch for initial Phase 2 data in H1 2027 and Phase 3 initiation in 2027 as key catalysts.
Price Chart
Executive Summary
Climb Bio reported additional Phase 1 data for CLYM116/MIL116, an anti-APRIL antibody for IgA nephropathy, at ASN Kidney Week 2026. The data showed sustained >90% free APRIL suppression through 12 weeks, ~70% Gd-IgA1 reduction, and a ~33-day half-life supporting Q12W dosing. The NAVIGATE-2 Phase 2 trial is enrolling with initial data expected H1 2027, and a global Phase 3 is planned for 2027.
Key Facts
- >90% free APRIL suppression sustained through 12 weeks after single SC dose ≥480 mg
- ~70% reduction in Gd-IgA1 and ~60% reduction in IgA at 12 weeks after 800 mg dose
- ~33-day half-life, 3.5x that reported for sibeprenlimab
- No dose-limiting toxicities, treatment-related SAEs, or hypogammaglobulinemia observed
- NAVIGATE-2 Phase 2 trial enrolling IgAN patients; initial data expected H1 2027
- Global Phase 3 trial expected to initiate in 2027 pending regulatory feedback
Financial Impact
Phase 1 data supports best-in-class profile for IgAN; positive readout de-risks Phase 2/3 and supports accelerated development. No financial figures disclosed.
Risk Factors
- Phase 2/3 clinical failure or safety signal could reverse positive early data
- Competition from other anti-APRIL therapies (e.g., sibeprenlimab) and approved IgAN treatments
- Regulatory feedback could delay global Phase 3 initiation
- Climb Bio may need additional capital to fund later-stage development
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3387603 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $10.92 | awaiting T+1 | — | $9.98 (−8.59%) |
Oct 23, 2026 3d ago | 8-K | $10.47 | awaiting T+1 | — | $9.98 (−4.66%) |
Oct 23, 2026 3d ago | Press Release | $10.34 | awaiting T+1 | — | $9.98 (−3.46%) |
Sep 22, 2026 4w ago | Institutional Cluster | $14.21 $12.52 | ▼ −11.89% | ▼ −11.17% | $9.98 (−29.75%) |
Sep 3, 2026 7w ago | 8-K | $14.59 $15.52 | ▲ +6.37% | ▲ +6.76% | $9.98 (−31.58%) |
Aug 14, 2026 10w ago | 8-K | $16.33 $17.44 | ▲ +6.80% | ▲ +7.27% | $9.98 (−38.87%) |
Aug 6, 2026 11w ago | 8-K | $14.00 $14.00 | · 0.00% | ▼ −0.61% | $9.98 (−28.70%) |
Jun 30, 2026 16w ago | 144 | $13.29 $12.90 | ▼ −2.93% | ▼ −2.80% | $9.98 (−24.89%) |
Jun 12, 2026 19w ago | 8-K | $11.49 $10.71 | ▲ +6.79% | ▲ +6.19% | $9.98 (+13.12%) |
Jun 12, 2026 19w ago | 424B5 | $11.49 $10.71 | ▲ +6.79% | ▲ +6.19% | $9.98 (+13.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers